PPBT PURPLE BIOTECH LTD. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1614744 · Fiscal year ends 12/31
Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $3.73M | $7.62M |
| SG&A expense | $3.25M | $3.18M |
| Interest expense | $982,000 | $483,000 |
| Net income | -$26.39M | -$7.24M |
| EPS (basic) | 0.03 | 4.44 |
| EPS (diluted) | 0.03 | 4.99 |
| Weighted avg. shares (diluted) | 480,053 | 1.64M |
| Balance sheet | ||
| Cash & equivalents | $8.72M | $7.40M |
| Short-term investments | — | $275,000 |
| Current assets | $9.87M | $8.91M |
| PP&E, netmay include right-of-use assets (IFRS) | $124,000 | $124,000 |
| Intangibles | $7.36M | $27.84M |
| Total assets | $17.57M | $37.04M |
| Current liabilities | $7.75M | $3.99M |
| Total liabilities | $7.91M | $4.13M |
| Shareholders' equity | $9.71M | $32.86M |
| Cash flow statement | ||
| Operating cash flow | -$5.66M | -$14.37M |
| Capital expenditure | $3,000 | — |
| Free cash flow | -$5.66M | — |
| Investing cash flow | $632,000 | $509,000 |
| Financing cash flow | $6.33M | $6.77M |
| Stock-based compensation | $309,000 | $582,000 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.